Table 3 |
||||||
|
Evolution of the patients with normal kidney function and RIFLE class 'risk' on admission broken by HES administration |
||||||
|
Normal kidney function on admission |
P |
RIFLE "risk" on admission |
P |
|||
|
HES - n = 45 |
HES + n = 28 |
HES - n = 54 |
HES + n = 37 |
|||
|
|
||||||
|
ICU treatments |
||||||
|
Catecholamines n (%) |
17 (37.7) |
19 (67.9) |
0.01 |
27 (50) |
27 (73) |
0.03 |
|
- Norepinephrine |
15 (33.3) |
18 (64.3) |
0.01 |
26 (48.1) |
25 (67.6) |
0.07 |
|
- Epinephrine |
1 (2.2) |
3 (10.7) |
0.12 |
2 (3.7) |
2 (5.4) |
1 |
|
- Dobutamine |
3 (6.7) |
4 (14.3) |
0.41 |
3 (5.5) |
4 (10.8) |
0.43 |
|
Activated protein C |
0 (0) |
0 (0) |
1 |
0 (0) |
0 (0) |
1 |
|
Hydrocortisone |
7 (15.5) |
7 (25) |
0.7 |
14 (25.9) |
13 (35.1) |
0.92 |
|
Mechanical ventilation |
28 (62.2) |
24 (85.7) |
0.03 |
36 (66.7) |
33 (89.2) |
0.01 |
|
Aminoglycosides |
8 (17.8) |
9 (32.1) |
0.16 |
15 (27.8) |
13 (35.1) |
0.45 |
|
Toxic dose aminoglycosides |
1 (2.2) |
1 (3.6) |
1 |
0 (0) |
0 (0) |
1 |
|
Glycopeptides |
7 (15.5) |
6 (21.4) |
0.54 |
13 (24.1) |
12 (32.4) |
0.38 |
|
Toxic dose glycopeptides |
1 (2.2) |
0 (0) |
1 |
3 (5.5) |
1 (2.7) |
0.64 |
|
Amphotericin B |
0 (0) |
0 (0) |
1 |
0 (0) |
0 (0) |
1 |
|
Radio-contrast agents |
7 (15.5) |
4 (14.3) |
1 |
5 (9.2) |
5 (13.5) |
0.73 |
|
Rhabdomyolysis |
4 (8.9) |
3 (10.7) |
1 |
6 (11.1) |
6 (16.2) |
0.47 |
|
Urinary obstruction |
1 (2.2) |
0 (0) |
1 |
0 (0) |
1 (2.7) |
0.4 |
|
Chemotherapy |
0 (0) |
0 (0) |
1 |
0 (0) |
1 (2.7) |
0.4 |
|
Evolution |
||||||
|
Shock from day 3 to day 21 |
3 (6.7) |
4 (14.3) |
0.41 |
6 (11.1) |
6 (16.2) |
0.54 |
|
Hemofiltration |
0 (0) |
2 (7.1) |
0.14 |
3 (5.5) |
3 (8.1) |
0.68 |
|
AKI |
5 (11.1) |
5 (17.9) |
0.49 |
6 (11.1) |
3 (8.1) |
0.73 |
|
Nosocomial infection |
8 (17.8) |
8 (28.6) |
0.28 |
11 (20.4) |
10 (27) |
0.45 |
|
Duration of shock (days (mean ± SD)) |
1.4 ± 2.6 |
4.2 ± 6.1 |
0.004 |
2.1 ± 3.1 |
3.8 ± 4.2 |
0.01 |
|
Duration of mechanical ventilation (days) |
8.4 ± 11.5 |
16.4 ± 18.6 |
0.02 |
13.3 ± 17.2 |
12.8 ± 16.8 |
0.1 |
|
Duration of hemofiltration (days) |
0 |
1.2 ± 4.3 |
0.07 |
0.9 ± 5.2 |
0.7 ± 2.8 |
0.38 |
|
Duration of ICU stay (days) |
12.5 ± 12.7 |
20.2 ± 20.3 |
0.09 |
14.8 ± 16.6 |
15.4 ± 16.6 |
0.27 |
|
ICU death |
9 (20) |
7 (25) |
0.62 |
12 (22.2) |
12 (32.4) |
0.28 |
|
|
||||||
|
AKI, acute kidney injury; HES, hydroxyethylstarch; RIFLE, Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease; SD, standard deviation. |
||||||
|
Boussekey et al. Critical Care 2010 14:R40 doi:10.1186/cc8920 |
||||||
